Hepatitis C News and Research

Latest Hepatitis C News and Research

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

Obesity, alcoholism, and chronic hepatitis all increase the risk of getting liver cancer, which is the third leading cause of cancer death worldwide. Obesity in particular is driving a significant increase in liver cancer in the United States.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

UT Southwestern Medical Center has launched the local arm of a national, multicenter study aimed at finding more effective treatments for alcoholic hepatitis, a disease of the liver that often leads to cirrhosis and death in severe cases.

19 Dec 2013

Researchers develop potential treatment for atherosclerosis

Researchers at Emory and Georgia Tech have developed a potential treatment for atherosclerosis that targets a master controller of the process.

18 Dec 2013

New report shows death rates for lung cancer dropping at a faster pace

The Annual Report to the Nation on the Status of Cancer, covering the period 1975, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years. The recent larger drop in lung cancer deaths is likely the result of decreased cigarette smoking prevalence over many years, and is now being reflected in mortality trends. The lung cancer death rate decline, as well as declines in colorectal, breast, and prostate cancer death rates, has also helped drive decreases in death rates for all cancers types combined, a trend that began about 20 years ago.

17 Dec 2013

Investigators, CTUs chosen to lead five HIV/AIDS clinical trials networks through 2021

Principal investigators and clinical trials units have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Total funding for the networks' leadership and the CTUs is expected to reach $225 million in 2014, the first year of operation.

17 Dec 2013

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

The National Institute of Allergy and Infectious Diseases has awarded two seven-year grants to Brigham and Women's Hospital to fund the AIDS Clinical Trial Group Network.

16 Dec 2013

Data show that HCV genotype-1 infected patients may benefit from faldaprevir

Data show that Boehringer Ingelheim’s second-generation protease inhibitor faldaprevir, when used in combination with pegylated interferon and ribavirin, was effective even with the presence of naturally-occurring mutant variants of the hepatitis C virus, such as the NS3 Q80K polymorphism

16 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

AudioEducator presents audio conferences on latest CPT coding updates for 2014

The providers want accurate reimbursement, whereas the payers want efficient claims processing. The ever-changing CPT® code set doesn't make your job easy. According to the American Medical Association (AMA), there will be 335 total code changes in 2014, to include 175 new codes, 107 revised codes, and 47 deleted codes.

12 Dec 2013

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

HCV antiviral therapy also improves diabetes outcomes

Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.

12 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

Revised Clinical Practice Guidelines on management of HCV published by EASL

The European Association for the Study of the Liver today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection. The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

9 Dec 2013

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

Diabetes was associated with an increased risk for developing a type of liver cancer called hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.

3 Dec 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

Researchers develop potential treatment for atherosclerosis

New report shows death rates for lung cancer dropping at a faster pace

Investigators, CTUs chosen to lead five HIV/AIDS clinical trials networks through 2021

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

Data show that HCV genotype-1 infected patients may benefit from faldaprevir

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

AudioEducator presents audio conferences on latest CPT coding updates for 2014

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Emergent BioSolutions enters into definitive agreement to acquire Cangene

HCV antiviral therapy also improves diabetes outcomes

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Revised Clinical Practice Guidelines on management of HCV published by EASL

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

IDSA released new guideline for vaccination of immunocompromised hosts

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in